Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs UV 1 (Primary) ; Granulocyte macrophage colony stimulating factor; Ipilimumab
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Ultimovacs AS
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
- 23 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Nov 2019.
- 23 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History